Fierce Pharma
MARCH 26, 2024
After three years, the crown jewel of Merck’s $11.5 billion acqu | After three years, the crown jewel of Merck’s $11.5 billion acquisition of Acceleron is ready to pay dividends. With the FDA’s approval of Winrevair (sotatercept) to treat pulmonary arterial hypertension (PAH), Merck is set to launch the first disease-modifying treatment for the condition.
pharmaphorum
MARCH 26, 2024
Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of underlying genetic mutations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MARCH 26, 2024
Maryland non-profit Caring Cross has unveiled a partnership with the Brazilian government that's designed to provide access to advanced cell and gene therapies for diseases like leukemia, lymphoma | Maryland nonprofit Caring Cross has unveiled a partnership with the Brazilian government which is designed to provide access to advanced CAR-T and gene therapies for diseases like leukemia, lymphoma and HIV infection—and in the process provide a manufacturing model that demonstrates how to reduc
MedCity News
MARCH 26, 2024
Merck drug Winrevair is the first in a new class of pulmonary arterial hypertension therapies that address a key signaling pathway behind the disease. The drug comes from Merck’s $11.5 billion acquisition of Acceleron Pharma.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
MARCH 26, 2024
Amgen’s arthritis blockbuster Enbrel already owns an undesirable spot on the list o | The state's new Prescription Drug Affordability Review Board voted to subject the blockbuster arthritis med to an upper price limit, which Amgen calls a violation of the company's constitutional rights.
European Pharmaceutical Review
MARCH 26, 2024
Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition. “We are excited to announce our fourth infectious disease vaccine programme with positive Phase III data,” stated Stéphane Bancel, Chief Executive Officer of Moderna. “mRNA
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Commerce
MARCH 26, 2024
A study of patients with the long-term conditions who are required to switch to high-deductible health plans could potentially be more likely to experience diabetes complications than those who stay in standard insurance plans.
Fierce Pharma
MARCH 26, 2024
Bristol Myers Squibb cuts hundreds of Mirati staffers months after closing $5.
MedCity News
MARCH 26, 2024
AI is meant to have a synergistic relationship with clinicians rather than replace them, pointed out David McSwain, chief medical information officer at UNC Health, during an interview at HIMSS24. In his view, both humans and AI are fallible, but their errors are usually of a different type — so both should be working together to reduce the overall error rate.
Fierce Pharma
MARCH 26, 2024
Demand for GLP-1 medicines from Eli Lilly and Novo Nordisk has exploded across the globe, resulting in on-and-off shortages in the U.S. and beyond. | Médecins Sans Frontières urged GLP-1 drug makers to "relinquish their stranglehold" on the products and license the meds to generics makers to boost access.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
MARCH 26, 2024
Nuvation Bio speeds up its path to becoming a commercial-stage biotech with a deal to acquire AnHeart Therapeutics and its late-stage lung cancer therapy taletrectinib
MedCity News
MARCH 26, 2024
During a panel discussion on GLP-1s at the Abarca Forward conference, one health executive stressed the importance of a food-as-medicine approach.
pharmaphorum
MARCH 26, 2024
MSD’s Winrevair (sotatercept) has become the first FDA-approved therapy for PAH that addresses the underlying mechanism behind the disease rather than its symptoms
MedCity News
MARCH 26, 2024
Scott Davis is the CEO of Ekso Bionics, an innovative medical device company making wearable exoskeletons for use in construction but perhaps, more importantly, to help people contending with spinal cord injury.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
MARCH 26, 2024
AstraZeneca’s Ultomiris has been approved by the FDA to treat rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), six months after an earlier application was turned down with a request for changes to the risk evaluation and mitigation strategy (REMS) for the drug.
Pharmaceutical Technology
MARCH 26, 2024
The US FDA has approved Alexion’s Ultomiris to treat adults with AQP4 Ab+ neuromyelitis optica spectrum disorder (NMOSD).
pharmaphorum
MARCH 26, 2024
Just four months after ending an 18-year stint as chief executive of BioMarin, Jean-Jacques Bienaimé has been named chairman of Owkin, a specialist in applying artificial intelligence to the discovery and development of drugs and diagnostics. Owkin said Bienaimé will help to grow the company, including taking it through its next fundraising round and expanding its drug discovery, drug development and diagnostics capabilities.
MedCity News
MARCH 26, 2024
In this episode, we’re joined by Millicent Gorham, CEO of the Alliance for Women’s Health and Prevention (AWHP). AWHP recently launched the EveryBODY Covered campaign, which is advocating for comprehensive coverage of obesity care. Gorham discusses the current state of obesity treatment for women and her goals for the campaign.
Pharmaceutical Technology
MARCH 26, 2024
The approval from Japan’s Ministry of Health, Labour, and Welfare (MHLW) is based on positive results from two studies.
MedCity News
MARCH 26, 2024
Disregarding novel developments on account of imperfection will postpone the advancement of scientific discovery.
PharmaTimes
MARCH 26, 2024
According to the World Health Organization, TB is responsible for over one million annual deaths
Pharmaceutical Technology
MARCH 26, 2024
Discover GlycoMimetics Inc.'s groundbreaking patent for treating cancer and related conditions with Formula (I) compound. Learn how this method can reduce chemotherapy side effects and improve patient outcomes.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaTimes
MARCH 26, 2024
The Companion+ Mobile Safety App will be rolled out to a further 115 users within the UK and US
PharmaVoice
MARCH 26, 2024
A vastly underdiagnosed rare disease presents a challenge to Alnylam’s commercial team, but a family health road trip has patients talking about their hereditary risk.
Clarify Health
MARCH 26, 2024
Historically it has been difficult, if not impossible, for patients to figure out prices for hospital services and procedures ahead of time. However, new regulations from the Centers for Medicare & Medicaid Service in 2021 aim to change that. Under these requirements, hospitals must provide clear prices for the items and services they offer and make them accessible online.
PharmExec
MARCH 26, 2024
In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, explore mixed trial results impact the confidence in their potential real-world effectiveness and potential market adoption.
Pharmaceutical Technology
MARCH 26, 2024
Discover Syros Pharmaceuticals' groundbreaking patent for treating cancer by targeting CDK7 with compounds of Formula (I). Learn about the innovative method and potential new treatment options for solid tumors.
PharmaVoice
MARCH 26, 2024
After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.
Pharmaceutical Technology
MARCH 26, 2024
Discover how Nurix Therapeutics' patent for bifunctional compounds targeting HPK1 activity offers a groundbreaking method for treating diseases, including cancer. Learn more about this innovative approach in pharmaceutical compositions.
PharmaTech
MARCH 26, 2024
The Vacaville, Calif., site acquisition gives Lonza one of the largest biologics manufacturing sites for mammalian cell-based therapies worldwide.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
313 
Let's personalize your content